NEWS RELEASE

Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference

2/2/2022

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.

Event:	Virtual 11th Annual SVB Leerink Global Healthcare Conference
Date:	Wednesday, February 16, 2022
Time:	4:20pm – 4:50pm ET

An audio webcast of this event will be available on the investor relations section of Evolus' website at **www.evolus.com**. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company with a customer-centric approach to delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at **www.evolus.com** and follow us on **LinkedIn**, **Twitter**, **Instagram** or **Facebook**.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: **david.erickson@evolus.com**

Source: Evolus, Inc.